肥胖症新型药物研发商Ousia Pharma获得巨额种子轮融资，以推进突破性肥胖症治疗的发展-动脉网

Ousia Pharma Secures Substantial Seed Financing Led by Omega Funds to Advance Groundbreaking Obesity Treatment

CISION 等信源发布 2025-05-06 15:00



可切换为仅中文







Ousia Pharma logo

欧西亚制药标志

Omega Funds Logo

欧米伽基金标志

Pioneering a first-in-class drug-targeting approach that leverages hormone analogues to deliver small-molecule neuroplasticity modulators directly to the brain's appetite control centers

开创了一种首创的药物靶向方法，利用激素类似物将小分子神经可塑性调节剂直接递送到大脑的食欲控制中心。

Financing will support the development of a dual-incretin-NMDA receptor antagonist conjugate through preclinical and early clinical development for the treatment of obesity

融资将支持一种双重肠促胰岛素-NMDA受体拮抗剂偶联物的开发，通过临床前和早期临床开发阶段，用于治疗肥胖症。

In conjunction with this financing, Prof. Sir

与此融资同时，профессор сэр

Mene Pangalos

梅内·潘加洛斯

, former Executive Vice President of BioPharmaceuticals R&D at AstraZeneca and current Omega Funds Venture Partner, as well as Dr. Elisabeth Bjӧrk, former Senior Vice President of Cardiovascular, Renal, and Metabolism R&D at AstraZeneca, and Dr.

，阿斯利康生物制药研发前执行副总裁、现任欧米伽基金风险合伙人，以及阿斯利康心血管、肾脏和代谢研发前高级副总裁伊丽莎白·比约克博士，和

Otello Stampacchia

奥泰罗·斯坦帕基亚

, Founder and Managing Director of Omega Funds, will join Ousia's Board of Directors

欧米加基金的创始人兼董事总经理将加入奥西亚公司的董事会。

COPENHAGEN

哥本哈根

, Denmark and

，丹麦和

BOSTON

波士顿

，

May 6, 2025

2025年5月6日

/PRNewswire/ -- Ousia Pharma, a next-generation biotech company pioneering a novel drug class for obesity, today announced the successful closing of a significant Seed financing round. The round, led and financed exclusively by Omega Funds, will support the preclinical and clinical development of Ousia's innovative once-weekly, dual-incretin-NMDA receptor antagonist conjugate.

/PRNewswire/ -- Ousia Pharma是一家下一代生物技术公司，致力于开发一类全新的肥胖症药物，今天宣布成功完成了重要的种子轮融资。本轮融资由Omega Funds独家领投，将支持Ousia创新的每周一次双促胰岛素-NMDA受体拮抗剂结合物的临床前和临床开发。

Additionally, the funding will drive the expansion of Ousia's proprietary technology, designed to target NMDA receptor small molecule modulators to specific neuronal populations..

此外，这笔资金将推动Ousia专有技术的扩展，该技术旨在针对特定神经元群体的NMDA受体小分子调节剂。

While

虽然

GLP-1

-based multi-agonists are transforming obesity management, significant challenges remain, including tolerability issues, variability in patient weight loss response, and weight regain. These hurdles underscore the urgent need for more effective pharmacological approaches.

基于多激动剂的疗法正在改变肥胖症的管理，但仍然存在显著的挑战，包括耐受性问题、患者体重减轻反应的差异以及体重反弹。这些障碍凸显了对更有效药物方法的迫切需求。

Ousia Pharma's innovative targeting concept is founded on the groundbreaking discovery that NMDA receptor antagonism holds promise for sustained weight loss. By ingeniously overcoming the challenge of non-specific targeting, Ousia has developed a novel strategy that conjugates small-molecule modulators to incretin hormones (Petersen et al., 2024, .

欧西亚制药的创新靶向概念基于一个突破性的发现，即NMDA受体拮抗作用有望实现持续减重。通过巧妙克服非特异性靶向的难题，欧西亚开发了一种新策略，将小分子调节剂与肠促胰岛素激素结合（彼得森等，2024）。

Nature

自然

). This pioneering work began in the research lab of Associate Professor

）。这项开创性工作始于副教授的实验室

Christoffer Clemmensen

克里斯托弗·克莱门森

at the

在

University of Copenhagen

哥本哈根大学

, culminating in the founding of Ousia Pharma in 2022 by

，最终在2022年由创立Ousia Pharma公司

Christoffer Clemmensen

克里斯托弗·克莱门森

，

Anders B. Klein

安德斯·B·克莱因

, and

，以及

Jonas Petersen

乔纳斯·彼得森

. The company secured its initial pre-seed investments from the BioInnovation Institute in

该公司从生物创新研究所获得了最初的预种子轮投资。

Copenhagen

哥本哈根

。

'We are excited to enter the next phase of Ousia Pharma's journey, advancing our groundbreaking platform towards clinical development,' said

“我们很高兴进入Ousia Pharma旅程的下一阶段，推动我们开创性的平台朝着临床开发迈进，”

Anders B. Klein

安德斯·B·克莱因

, PhD, CEO of Ousia Pharma. 'The strong support from Omega Funds enables us to accelerate the preclinical and clinical validation of our peptide-drug conjugate program, bringing us closer to a transformative treatment for obesity. With a unique mechanism designed to enhance efficacy while addressing key challenges like tolerability, we believe our approach has the potential to set a new standard in obesity therapeutics.'.

，博士，Ousia Pharma首席执行官。“Omega Funds的大力支持使我们能够加速多肽药物偶联项目的临床前和临床验证，使我们更接近于为肥胖症提供一种变革性的治疗方法。凭借旨在提高疗效的独特机制，同时解决耐受性等关键挑战，我们相信我们的方法有潜力在肥胖症治疗领域树立新标准。”

'We are thrilled to support Ousia Pharma as they advance a truly innovative approach to obesity treatment,' said

“我们非常高兴能够支持奥西亚制药，因为他们正在推进一种真正创新的肥胖症治疗方法，”

Otello Stampacchia

奥泰罗·斯坦帕基亚

, founder and Managing Director at Omega Funds. 'Their novel dual-incretin-NMDA receptor antagonist conjugate represents a promising breakthrough in tackling several of the limitations of existing obesity treatments. We believe Ousia's pioneering science and accomplished team position the company for meaningful impact and value creation, and we are excited to be part of their journey.'.

Omega Funds的创始人兼董事总经理。“他们新颖的双重抑制素-NMDA受体拮抗剂结合物代表了在应对现有肥胖症治疗的一些局限性方面取得了有希望的突破。我们相信Ousia的开创性科学和经验丰富的团队将使公司产生重大影响并创造价值，我们很高兴能成为他们旅程的一部分。”

Otello Stampacchia

奥泰罗·斯坦帕基亚

, along with pharmaceutical industry veterans Dr. Elisabeth Björk and Prof. Sir

，以及制药行业资深人士伊丽莎白·比约克博士和教授爵士

Mene Pangalos

梅内·潘加洛斯

, will join the Ousia Pharma board. Pangalos was previously Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, and Bjork was previously SVP of Cardiovascular, Renal, and Metabolism R&D at AstraZeneca, where she led the company's

，将加入奥西亚制药董事会。潘加洛斯此前曾担任阿斯利康生物制药研发执行副总裁，比约克此前曾担任阿斯利康心血管、肾脏和代谢研发高级副总裁，她领导了公司的

GLP-1

drug development efforts. They will join existing board members

药物开发工作。他们将加入现有的董事会成员行列。

Ian Laquian

伊恩·拉奎安

, CEO of Kariya Pharmaceuticals, and

，加里亚制药公司的首席执行官，和

Christoffer Clemmensen

克里斯托弗·克莱门森

, Associate Professor within the Novo Nordisk Foundation Center for Basic Metabolic Research at the

，诺和诺德基金会基础代谢研究中心的副教授，在

University of Copenhagen

哥本哈根大学

and Chief Scientific Officer at Ousia Pharma.

Ousia制药公司的首席科学官。

Prof. Sir Mene Pangalos said, 'Having worked in the pharmaceutical industry for decades and witnessed many targets emerge and fade in the cardiometabolic space, I can confidently say that the approach taken by Ousia Pharma is one of the most innovative I have encountered. I am extremely excited to contribute to bringing Ousia Pharma's technology to patients.'.

彭卡洛斯爵士表示：“在制药行业工作了几十年，见证了心血管代谢领域许多靶点的出现与消逝，我可以肯定地说，Ousia Pharma 所采取的方法是我见过最具创新性的之一。我非常激动能够为将 Ousia Pharma 的技术带给患者做出贡献。”

About Ousia Pharma

关于奥西亚制药

Ousia Pharma, a private biotech company spun out from the

奥西亚制药，一家从...分离出来的私人生物技术公司

University of Copenhagen

哥本哈根大学

, is developing innovative peptide-drug conjugates to treat obesity and metabolic diseases. The company has pioneered a first-in-class drug-targeting approach that leverages incretin hormone analogues to deliver small-molecule neuroplasticity modulators directly to the brain's appetite control centers.

，正在开发创新的肽药物偶联物以治疗肥胖症和代谢疾病。该公司开创了一种首创的药物靶向方法，利用肠促胰岛素激素类似物将小分子神经可塑性调节剂直接递送到大脑的食欲控制中心。

This groundbreaking strategy aims to provide transformative treatments for patients suffering from obesity and its associated cardiometabolic conditions. For more information, please visit .

这一开创性策略旨在为患有肥胖症及其相关心代谢疾病的患者提供变革性的治疗方法。欲了解更多信息，请访问。

www.ousiapharma.com

。

About Omega Funds

关于欧米茄基金

Founded in 2004, Omega Funds is a leading international venture capital firm that creates and invests in life sciences companies that target our world's most urgent medical needs. Omega focuses on identifying and supporting companies through value inflection points across the full arc of innovation, from company formation through clinical milestones and commercial adoption.

成立于2004年的欧米伽基金是一家领先国际风险投资公司，专注于创立和投资针对世界最紧迫医疗需求的生命科学公司。欧米伽致力于识别并支持公司在创新全过程中的价值拐点，从公司成立到临床里程碑及商业化应用。

Omega Funds' portfolio companies have brought over 50 products to market in multiple therapeutic areas, including oncology, rare diseases, precision medicine and others. Please visit .

Omega Funds的投资组合公司已将50多种产品推向市场，涵盖肿瘤学、罕见病、精准医学等多个治疗领域。请访问。

www.omegafunds.com

for additional information.

获取更多信息。

Contacts

联系人

Ousia Pharma

奥西亚制药

Anders Bue Klein

安德斯·布伊·克莱因

Co-founder & CEO, Ousia Pharma

联合创始人兼首席执行官，Ousia制药公司